Interleukin-2: Its Biology and Clinical Application in Patients with Cancer

References

• Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–1008
   PubMed Web of Science ®Google Scholar
• Ruscetti F. W., Morgan D. A., Gallo R. C. Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol 1977; 119: 131–138
   PubMed Web of Science ®Google Scholar
• Gillis S., Smith K. A. Long term culture of tumor-specific cyto-toxic T cells. Nature 1977; 268: 154–156
   PubMed Web of Science ®Google Scholar
• Tees R., Schreier M. H. Selective reconstitution of nude mice with long term cultured and cloned specific helper T cells. Nature 1980; 283: 780–781
   PubMed Web of Science ®Google Scholar
• Cheever M. A., Greenberg P. D., Fefer A., et al. Augmentation of the antitumore therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified inlerleukin-2. J Exp Med 1982; 155: 968–980
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Matsui H., Fujita T., et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302: 305–310
   PubMed Web of Science ®Google Scholar
• Devos R., Plaetinck G., Cheroutre H., et al. Molecular cloning of human interleukin-2 cDNA and its expression in E. coli. Nucleic Acids Res 1983; 11: 4307–4323
   PubMed Web of Science ®Google Scholar
• McGuire K. L., Yang J. A., Rothenberg E. V. Influence of activating stimulus on functional phenotype: Interleukin-2 mRNA accumulation differentially induced by ionophore and receptor ligands in subsets of murine T cells. Proc Natl Acad Sci USA 1988; 85: 6503–6507
   PubMed Web of Science ®Google Scholar
• Taira S., Matsui M., Hayakawa K., et al. Interleukin-2 secretion by B-cell lines and splenic B cells stimulated with calcium ionophore and phorbol ester. J Immunol 1987; 139: 2957–2964
   PubMed Web of Science ®Google Scholar
• O'Shea J. J., Harford J. B., Klausner R. D. Identification and characterization of the phosphatidylinositol kinase in membranes of murine T lymphocytes. J Immunol 1986; 137: 971–976
   PubMed Web of Science ®Google Scholar
• Imboden J. B., Stobo J. D. Transmembrane signalling by the T-cell antigen receptor: Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. J Exp Med 1985; 161: 446–456
   PubMed Web of Science ®Google Scholar
• Sussman J. J., Merćep M., Saito T., et al. Dissociation of phospho-inositide hydrolysis and calcium fluxes from the biological responses of a T-cell hybridoma. Nature 1988; 334: 625–628
   PubMed Web of Science ®Google Scholar
• Goldsmith M. A., Weiss A. Early signal transduction by the antigen receptor without commitment to T-cell activation. Science 1988; 240: 1029–1031
   PubMed Web of Science ®Google Scholar
• Janeway C. Immunogenicity signals 1,2,3 … and 0____. Immunol Today 1989; 10: 283–286
   PubMedGoogle Scholar
• Weaver C. T., Unanue E. R. The costimulatory function of antigen presenting cells. Immunol Today 1990; 11: 49–55
   PubMedGoogle Scholar
• Sprent J., Schaefer M. Antigen presenting cells for unprimed T cells. Immunol Today 1989; 10: 17–23
   PubMedGoogle Scholar
• Mizel S. B. Interleukin-1 and T-cell activation. Immunol Today 1987; 8: 330–332
   PubMedGoogle Scholar
• Chu E. T., Lareau M., Rosenwasser L. J., et al. Antigen presentation by EBV-B cells to resting and activated T cells: Role of interleukin-1. J Immonol 1985; 134: 1676–1681
   PubMed Web of Science ®Google Scholar
• Ceuppens J. L., Baroja M. L., Lorré K., et al. Human T-cell activation with phytohemagglutinin. J Immunol 1988; 141: 3868–3874
   PubMed Web of Science ®Google Scholar
• Lorré K., Damme J. V., Verwilghen J., et al. IL-6 is an accessory signal in the alternative CD2-mediated pathway of T-cell activation. J Immunol 1990; 144: 4681–4687
   PubMed Web of Science ®Google Scholar
• Van Seventer G. A., Shimizu Y., Morgan K. J., et al. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor-mediated activation of resting T cells. J Immunol 1990; 144: 4579–4586
   PubMed Web of Science ®Google Scholar
• Figdor C. G., Kooyk Y. V., Keizer G. D. On the mode of action of LFA-1. Immunol Today 1990; 11: 277–280
   PubMedGoogle Scholar
• Makgoba M. W., Sanders M. E., Shaw S. The CD2-LFA3 and LFA1-ICAM pathways: Relevance to T-cell recognition. Immunol Today 1989; 10: 417–422
   PubMedGoogle Scholar
• Fraser J. D., Irving B. A., Crabtree G. R., et al. Regulation of interleukin-2 gene enhancer activity by the T-cell accessory molecule CD28. Science 1991; 251: 313–316
   PubMed Web of Science ®Google Scholar
• Lindsten T., June C. H., Ledbetter A., et al. Regulation of lymphokine messenger RNA stability by a surface-mediated T-cell activation pathway. Science 1989; 244: 339–343
   PubMed Web of Science ®Google Scholar
• June C. H., Ledbetter J. A., Lindsten T., et al. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J Immunol 1989; 143: 153–161
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Clark E. A., Ledbetter J. A. T-cell antigen CD28 mediates adhesion with B cell by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031–5035
   PubMed Web of Science ®Google Scholar
• Williams T. M., Eisenberg L., Burlein J. E., et al. Two regions within the human IL-2 gene promoter are important for inducible IL-2 expression. J Immunol 1988; 141: 662–666
   PubMed Web of Science ®Google Scholar
• Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol 1988; 6: 439–464
   PubMed Web of Science ®Google Scholar
• Crabtree G. R. Contingent genetic regulatory events in T-lymphocyte activation. Science 1989; 243: 355–361
   PubMed Web of Science ®Google Scholar
• Durand D. B., Shaw J. P., Bush M. R., et al. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol 1988; 8: 1715–1724
   PubMed Web of Science ®Google Scholar
• Shaw J. P., Utz P. J., Durand D. B., et al. Identification of a putative regulator of early T-cell activation genes. Science 1988; 241: 202–205
   PubMed Web of Science ®Google Scholar
• Serfling E., Barthelmäs R., Pfeuffer I., et al. Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin-2 gene in T lymphocytes. EMBO J 1989; 8: 465–473
   PubMed Web of Science ®Google Scholar
• Lenardo M. J., Baltimore D. NK-KB: A pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227–229
   PubMed Web of Science ®Google Scholar
• Schwartz R. H. A cell culture model for T-lymphocyte clonal anergy. Science 1990; 248: 1349–1356
   PubMed Web of Science ®Google Scholar
• Sherblom A. P., Sathyamoorthy N., Decker J. M., et al. IL-2, a lectin with specificity for high mannose glycopeptides. J Immunol 1989; 143: 939–944
   PubMed Web of Science ®Google Scholar
• Brandhuber B. J., Boone T., Kenney W. C., et al. Three-dimensional structure of interleukin 2. Science 1987; 238: 1707–1709
   PubMed Web of Science ®Google Scholar
• Bazan J. F. Unraveling the structure of IL-2. Science 1992; 257: 410–412
   PubMed Web of Science ®Google Scholar
• Bailon P., Weber D. V. Receptor-affinity chromatography. Nature 1988; 335: 839–840
   PubMed Web of Science ®Google Scholar
• Sauve G. JK, Bailon P., Tsien W. H., . Structure activity relationships of human IL-2: Identification of residues that bind the IL-2 receptor. The Biology and Clinical Applications of Interleukin-2, R. C. Rees, et al. IRL Press, Oxford 1990; 7–14
   Google Scholar
• Wang H-M, Smith K. A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166: 1055–1069
   PubMed Web of Science ®Google Scholar
• Reem G. H., Yeh N-H. Interleukin-2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science 1984; 225: 429–430
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., Goldman C. K., Robb R. J., et al. Expression of interleukin-2 receptors on activated human B cells. J Exp Med 1984; 160: 1450–1466
   PubMed Web of Science ®Google Scholar
• Holier W., Grunow R., Stockinger H., et al. Recombinant interferon-gamma induces interleukin-2 receptors on human peripheral blood monocytes. J Immunol 1986; 136: 2171–2175
   PubMed Web of Science ®Google Scholar
• Holier W., Goldman C. K., Casabo L., et al. Expression of functional IL-2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol 1987; 138: 2917–2922
   PubMed Web of Science ®Google Scholar
• Hoyos B., Ballard D. W., Böhnlein E., et al. Kappa-B-specific DNA-binding proteins: Role in the regulation of human interleukin-2 gene expression. Science 1989; 244: 457–460
   PubMed Web of Science ®Google Scholar
• Scholz W., Allman A. Synergistic induction of interleukin-2 receptor (Tac) expression on YT cells by interleukin 1 or tumor necrosis factor α in combination with cAMP-inducing agents. Cell Signal 1989; 1: 367–375
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A., Andrus L., Steinman R. M. Lymphokine and non-lymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 1986; 163: 922–937
   PubMed Web of Science ®Google Scholar
• Isakov N., Altman A. Tumor promoters in conjunction with calcium ionophores mimic antigenic stimulalion by reactivation of alloantigen-primed murine T lymphocytes. J Immunol 1985; 135: 3674–3680
   PubMed Web of Science ®Google Scholar
• Kuziel W. A., Green W. C. Interleukin-2 and the IL-2 receptor: New insights into structure and function. J Invest Dermatol 1990; 94: 27S–32S
   PubMed Web of Science ®Google Scholar
• Lowenthal J. W., Greene W. C. Contrasting IL-2 binding properties of the α (p55) and β (p70) protein subunits of the human high-affinily IL-2 receptor. J Exp Med 1987; 166: 1156–1161
   PubMed Web of Science ®Google Scholar
• Smilh K. A. Inlerleukin-2: Inception, impacl and implications. Science 1988; 240: 1169–1176
   PubMedGoogle Scholar
• Saragovi M., Malek T. R. Evidence for additional subunits associated lo the mouse interleukin-2 receptor p55/p75 complex. Proc Natl Acad Sci USA 1990; 87: 11–15
   PubMed Web of Science ®Google Scholar
• Kamio K., Uchiyama T., Arima N., et al. Role of alpha chain-IL-2 complex in the formalion of the ternary complex of IL-2 and high-affinity IL-2 receptor. Int Immunol 1990; 2: 521–530
   PubMed Web of Science ®Google Scholar
• D'Andrea A. D., Fasman G. D., Lodish H. F. Erythropoietin receptor and IL-2 receptor β chain: A new receptor family. Cell 1989; 58: 1023–1024
   PubMed Web of Science ®Google Scholar
• Mosley B., Beckmann M. P., March C. J., et al. The murine IL-4 receptor: Molecular cloning and characterization of secreted and membrane-bound forms. Cell 1989; 59: 335–348
   PubMed Web of Science ®Google Scholar
• Yamasaki K., Taga T., Hirata Y., et al. Cloning and expression of the human interleukin-6(BSF-2/IFNβ 2) receptor. Science 1988; 241: 825–828
   PubMed Web of Science ®Google Scholar
• Ito N., Yonehara S., Schreurs J., et al. Cloning of an IL-3 receptor gene: A member of a distinct receptor gene family. Science 1990; 247: 324–327
   PubMed Web of Science ®Google Scholar
• Gearing D. P., King J. A., Cough N. M., et al. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J 1989; 8: 3667–3676
   PubMed Web of Science ®Google Scholar
• Hatakeyama M., Mori H., Doi T., et al. A restricted cytoplasmic region of IL-2 receptor β chain is essential for growth signal transduction but not for ligand binding and internalization. Cell 1989; 59: 837–845
   PubMed Web of Science ®Google Scholar
• Bazan J. F. Structural design and molecular evolution of a cyto-kine receptor superfamily. Proc Natl Acad Sci USA 1990; 18: 6934–6938
   Google Scholar
• Cosman D., Lyman S. D., Idzerda R. L., et al. A new cytokine receptor superfamily. Trends Biochem Sci 1990; 15: 265–270
   PubMed Web of Science ®Google Scholar
• Espinoza-Delgado I., Ortaldo J. R., Winkler-Pickett W., et al. Expression and role of p75 interleukin-2 receptor on human mono-cytes. J Exp Med 1990; 171: 1821–1826
   PubMed Web of Science ®Google Scholar
• Nishi M., Ishida Y., Honjo T. Expression of functional interleukin-2 receptors in human light chain/Tac transgenic mice. Nature 1988; 331: 267–269
   PubMed Web of Science ®Google Scholar
• Yagita H., Nakata M., Azuma A., et al. Activation of peripheral blood T cells via the p75 interleukin-2 receptor. J Exp Med 1989; 170: 1445–1450
   PubMed Web of Science ®Google Scholar
• Siegel J. P., Sharon M., Smith P. L., et al. The IL-2 receptor β chain: Role in mediating signals for LAK, NK, and proliferative activities. Science 1987; 238: 75–78
   PubMed Web of Science ®Google Scholar
• Caliguiri M. A., Zmudzinas A., Maneley T. J., et al. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes: Identification of a novel natural killer cell subset with high-affinity receptors. J Exp Med 1990; 171: 1509–1526
   PubMed Web of Science ®Google Scholar
• Zubler R. H., Lowenthal J. W., Erard F., et al. Activated B cells express receptors for, and proliferate in response to, pure interleukin-2. J Exp Med 1984; 160: 1170–1183
   PubMed Web of Science ®Google Scholar
• Benveniste E. N., Merrill J. E. Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature 1986; 321: 610–613
   PubMed Web of Science ®Google Scholar
• Malkovsky M., Loveland B., North M., et al. Recombinant interleukin-2 directly augments the cytotoxicity of human mono-cytes. Nature 1987; 325: 262–265
   PubMed Web of Science ®Google Scholar
• Steiner G., Tschachler E., Tani M., et al. Interleukin-2 receptors on cultured murine epidermal Langerhans cells. J Immunol 1986; 137: 155–159
   PubMed Web of Science ®Google Scholar
• Takeshita T., Asao H., Ohtani K., et al. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257: 379–382
   PubMed Web of Science ®Google Scholar
• Smith K. A., Cantrell D. A. Interleukin 2 regulates its own receptors. Proc Natl Acad Sci USA 1985; 82: 864–868
   PubMed Web of Science ®Google Scholar
• Smith K. A. The interleukin 2 receptor. Advances in Immunology, Vol 42, F. J. Dixon. Academic Press, San Diego 1988; 165–179
   Google Scholar
• Mills G., Stewart D. J., Mellors A., et al. Interleukin-2 does not induce phosphatidylinositol hydrolysis in activated T cells. J Immunol 1986; 136: 3019–3024
   PubMed Web of Science ®Google Scholar
• Mills G. B., Girard P., Grinstein S., et al. Interleukin-2 induced proliferation of T lymphocyte mutants lacking protein kinase C. Cell 1988; 55: 91–100
   PubMed Web of Science ®Google Scholar
• Tigges M. A., Casey L. S., Koshland M. E. Mechanisms of interleukin-2 signaling: Mediation of different outcomes by a single receptor and transduction pathway. Science 1989; 243: 781–786
   PubMed Web of Science ®Google Scholar
• Szöllösi J., Damjanovich S., Goldman C. K., et al. Flow cytometric resonance energy transfer measurements support the association of a 95 kDa peptide termed T27 with the 55kDa Tac peptide. Proc Natl Acad Sci USA 1987; 84: 7246–7251
   PubMed Web of Science ®Google Scholar
• Edidin M., Aszalos A., Damjanovich S., et al. Lateral diffusion measurements give evidence for association of the Tac peptide of the IL-2 receptor with the T27 peptide in the plasma membrane of HUT-102-B2 T cells. J Immunol 1988; 141: 1206–1210
   PubMed Web of Science ®Google Scholar
• Herrmann F., Diamanstein T. The mouse high-affinity IL-2 receptor complex. I. Evidence for a third molecule, the putative γ chain, associated with the α-and/or β-chain of the receptor. Immunobiology 1987; 175: 145–158
   PubMed Web of Science ®Google Scholar
• Saragovi H., Malek T. R. The murine IL-2 receptor: Irreversible cross-linking of radiolabeled IL-2 to high-affinity IL-2 receptors reveals a non-covalently associated subunit. J Immunol 1987; 139: 1918–1926
   PubMed Web of Science ®Google Scholar
• Nakamura Y., Inamoto T., Sugie K., et al. Mitogenicity and down-regulation of high-affinity IL-2 receptor by YTA-1 and YTA-2, monoclonal antibodies that recognize 75-kDa molecules on human large granular lymphocytes. Proc Natl Acad Sci USA 1989; 86: 1318–1322
   PubMed Web of Science ®Google Scholar
• Sharon M., Gnarra J. R., Leonard W. J. A 100-kilodalton protein is associated with the murine interleukin-2 receptor: Biochemical evidence that p100 is distinct from the α and β chains. Proc Natl Acad Sci USA 1990; 87: 4869–4873
   PubMed Web of Science ®Google Scholar
• Colamonici O. R., Neckers L. M., Rosolen A. Putative γ subunit of the IL-2 receptor is detected in low, intermediate, and high-affinity IL-2 receptor-bearing cells. J Immunol 1990; 145: 155–160
   PubMed Web of Science ®Google Scholar
• Horak I. D., Gress R. E., Lucas P. J., et al. T-lymphocyte interleukin-2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. Proc Natl Acad Sci USA 1991; 88: 1996–2000
   PubMed Web of Science ®Google Scholar
• Hatakeyama M., Kono T., Kabayashi N., et al. Interaction of the IL-2 receptor with the src-family kinase p56lck: Identification of novel intermolecular association. Science 1991; 252: 1523–1528
   PubMed Web of Science ®Google Scholar
• Turner B., Rapp U., App H., et al. Interleukin-2-induced tyrosine phosphorylation and activation of p72–74 Raf-1 kinase in a T-cell line. Proc Natl Acad Sci USA 1991; 88: 1227–1231
   PubMed Web of Science ®Google Scholar
• Zmuidzinas A., Mamon H. J., Roberts T. M., et al. Interleukin-2-triggered Raf-1 expression, phosphorylation, and associated kinase activity increase through Gl and S in CD3-stimulated primary human T cells. Mol Cell Biol 1991; 11: 2794–2803
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., et al. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984; 160: 1147–1159
   PubMed Web of Science ®Google Scholar
• Nakanishi K., Malek T. P., Smith K. A., et al. Both interleukin 2 and a second T-cell derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J Exp Med 1984; 160: 1605–1621
   PubMed Web of Science ®Google Scholar
• Stötter H., Rude E., Wagner H. T-cell factor (interleukin-2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol 1980; 10: 719–722
   PubMed Web of Science ®Google Scholar
• Kennedy M., Wassmer P., Erb P. A novel role for interleukin 2 in antibody response: Down regulation of T helper cell activity. J Immunol 1987; 139: 110–113
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Gottlieb D. J., Bianchi A. CM, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Kasid A., Director E. P., Rosenberg S. A. Induction of endogenous cytokine mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 1989; 143: 736–739
   PubMed Web of Science ®Google Scholar
• Harada M., Mori K., Nishimoto H. Suppressive and augmentative effects of recombinant human interleukin 2 upon delayed type of hypersensitivity in the mouse. Inflammation 1986; 10: 167–174
   PubMed Web of Science ®Google Scholar
• Jablons D., Bolton E., Merlins S., et al. IL-2 based immunother-apy alters circulating neutrophil Fc receptor expression and chemotaxis. J Immunol 1990; 144: 3630–3636
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Spiess P. J., Schwarz S. In vivo administration of IL-2 enhances specific alloimmune responses. Transplantation 1983; 35: 631–634
   PubMed Web of Science ®Google Scholar
• Clason A. E., Duarte A. JS, Kupiec-Weglinski J. W., et al. Restoration of allograft responsiveness in B rats by IL-2 and/or adherent cells. J Immunol 1982; 129: 252–260
   PubMed Web of Science ®Google Scholar
• Rouse B. T., Miller L. S., Turtinen L., et al. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2. J Immunol 1985; 134: 926–930
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Mule J. J., Spiess P. J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose, recombinant interleukin 2. J Exp Med 1985; 161: 1169–1188
   PubMed Web of Science ®Google Scholar
• Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant IL-2. Cancer Res 1985; 45: 3735–3741
   PubMed Web of Science ®Google Scholar
• Mule J. J., Shu S., Rosenberg S. A. The antitumor efficacy of lymphokine-activated killer cells and recombinanl interleukin 2 in vivo. J Immunol 1985; 135: 646–652
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Spiess P. J., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–1321
   PubMed Web of Science ®Google Scholar
• Alex-Martinez J. E., Alvarez-Mon M., Merino F., et al. Decreased TcR-CD3+ T-cell numbers in healthy, aged humans. Evidence that T-cell defects are masked by a reciprocal increase of TcR-CD3 ∼ CD2+ natural killer cells. Eur J Immunol 1988; 18: 1827–1830
   PubMed Web of Science ®Google Scholar
• Teodorczyk-Injeyan J. A., Sparkes B. G., Mills G. B., et al. Impairment of T-cell activation in burn patients: A possible mechanism of thermal injury-induced immunosuppression. Clin Exp Immunol 1986; 65: 570–581
   PubMed Web of Science ®Google Scholar
• Merluzzi V. J., Welk K., Savage D. M., et al. Expansion of cyclo-phosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol 1983; 131: 806–809
   PubMed Web of Science ®Google Scholar
• Kay N. E., Kaplan M. E. Defective T-cell responsiveness in chronic lymphocytic leukemia: Analysis of activation events. Blood 1986; 67: 578–581
   PubMed Web of Science ®Google Scholar
• Soulillou J. P., Peyronnet P., LeMauff B., et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; 1: 1339–1342
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–485
   PubMed Web of Science ®Google Scholar
• Eberlein T. J., Schoof D. D., Jung S-E, et al. A new regimen of interleukin-2 and lymphokine-activated killer cells. Efficacy without significant toxicity. Arch Intern Med 1988; 148: 2571–2576
   PubMed Web of Science ®Google Scholar
• Steis R., Urba W., Vander Molen L. A., et al. Intraperitoneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 1990; 8: 1618–1629
   PubMed Web of Science ®Google Scholar
• Hession C., Decker J. M., Sherblom A. P., et al. Uromodulin (Tamm-Horsfall glycoprotein): A renal ligand for lymphokines. Science 1987; 237: 1479–1484
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Frana L. W., Sharrow S. O., et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell-line derived interleukin 2. J Immunol 1985; 134: 157–166
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Rosenberg S. A. Interleukin 2 as a pharmacologic reagent. Interleukin 2, K. A. Smith. Academic Press, New York 1988; 237–294
   Google Scholar
• Lotze M. T., Custer M. C., Sharrow S. O., et al. In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987; 47: 2188–2195
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Matory Y. L., Ettinghausen S. E., et al. In vivo administration of purified human IL-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865–2875
   PubMed Web of Science ®Google Scholar
• Cotran R. S., Pober J. S., Gimbrone M. A., et al. Endothelial activation during interleukin-2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988; 140: 1883–1888
   PubMed Web of Science ®Google Scholar
• Belldegrun A., Webb D. E., Austin H. A., et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106: 817–822
   PubMed Web of Science ®Google Scholar
• Lee R. E., Lotze M. T., Skibber J. M., et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989; 7: 7–20
   PubMed Web of Science ®Google Scholar
• Baars J. W., Hack C. E., Wagstaff J., et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br J Cancer 1992; 65: 96–101
   PubMed Web of Science ®Google Scholar
• Fisher B., Keenan A. M., Garra B. S., et al. Interleukin-2 produces profound, reversible cholestasis: A detailed analysis in treated cancer patients. J Clin Oncol 1989; 7: 1852–1862
   PubMed Web of Science ®Google Scholar
• Denicoff K. D., Durkin T. M., Lotze M. T., et al. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 1989; 69: 402–410
   PubMed Web of Science ®Google Scholar
• Weiss G. R., Margolin K. A., Aronson F. R., et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275–281
   PubMed Web of Science ®Google Scholar
• Thompson J. A., Shulman K. L., Benyunes M. C., et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer cell therapy for matastatic renal cell carcinoma. J Clin Oncol 1992; 10: 960–968
   PubMed Web of Science ®Google Scholar
• Geertsen P. F., Hermann G. G., van der Maase H., et al. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study. J Clin Oncol 1992; 10: 753–759
   PubMed Web of Science ®Google Scholar
• Muul L. M., Spiess P. J., Director E. P., et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989–995
   PubMed Web of Science ®Google Scholar
• Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytol-ysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714–3725
   PubMed Web of Science ®Google Scholar
• Topalian S. L., Solomon D., Avis F. P., et al. Immunotheraphy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 1988; 6: 839–853
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Packard B. S., Aebersold P. M., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immu-notherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–1680
   PubMed Web of Science ®Google Scholar
• Asher A., Mule J. J., Reichert C. M., et al. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963–974
   PubMed Web of Science ®Google Scholar
• Palladino M. A., Shalaby M. R., Kramer S. M., et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987; 138: 4023–4032
   PubMed Web of Science ®Google Scholar
• Creasey A. A., Reynolds M. T., Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986; 46: 5687–5690
   PubMed Web of Science ®Google Scholar
• McIntosh J. K., Mule J. J., Merino M. J., et al. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res 1988; 48: 4011–4017
   PubMed Web of Science ®Google Scholar
• Kataoka T., Matsuura N., Oh-Hashi F., et al. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors. Cancer Res 1985; 45: 3548–3553
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Reuben J., Manning J. T., et al. α interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15–18
   PubMed Web of Science ®Google Scholar
• Spiegel R. J. The α interferons: Clinical overview. Semin Oncol 1987; 14: 1–12
   PubMed Web of Science ®Google Scholar
• Cameron R. B., McIntosh J. K., Rosenberg S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48: 5810–5817
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Körfer A., Franks C. R., et al. Home therapy with recombinant interleukin-2 and interferon-alpha in advanced human malignancies. Lancet 1990; 335: 1509–1512
   PubMed Web of Science ®Google Scholar
• Lissoni P., Barni S., Ardizzoia A., et al. Second line therapy with low-dose, subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 1992; 28: 92–96
   PubMed Web of Science ®Google Scholar
• Sleijfer D. T., Janssen R. AJ, Buter J., et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10: 1119–1123
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Kirchner H. The outpatient use of recombinant human interleukin-2 and interferon alpha-2b in advanced malignancies. Eur J Cancer 1991; 27(Suppl 4)S88–S91
   PubMedGoogle Scholar
• Margolin K. A., Aronson F. R., Sznol M., et al. Phase II trial of high-dose interleukin 2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immu-nother 1991; 10: 214–220
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Vaickus L., Friedman N., et al. Interleukin 2 hymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991; 10: 141–146
   PubMed Web of Science ®Google Scholar
• Bernstein Z. P., Goldrosen M. H., Vaickus L., et al. Interleukin 2 with ex vivo activated killer cells: Therapy of advanced non-small-cell lung cancer. J Immunother 1991; 10: 383–387
   PubMed Web of Science ®Google Scholar
• Keilholz U., Schlag P., Tilgen W., et al. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 1992; 69: 2172–2175
   PubMed Web of Science ®Google Scholar
• Schwartzentruber D. J., Topalian S. L., Mancini M., et al. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991; 146: 3674–3681
   PubMed Web of Science ®Google Scholar
• Barth R. J., Mule J. J., Spiess P. J., et al. Interferon-gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647–658
   PubMed Web of Science ®Google Scholar
• Tepper R. I., Pattengale P. K., Lader P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Golumbek P. T., Lazenby A. J., Levitsky Al, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar